Welcome to our dedicated page for Precigen news (Ticker: PGEN), a resource for investors and traders seeking the latest updates and insights on Precigen stock.
Precigen, Inc. reports developments as a commercial-stage biopharmaceutical company advancing precision medicines for difficult-to-treat diseases. Its news centers on PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved therapy for adults with recurrent respiratory papillomatosis, including commercialization, access, reimbursement, medical-publication updates, and adoption by treating physicians.
Company updates also cover financial results, business presentations, and pipeline activity across immuno-oncology, autoimmune disorders, and infectious diseases. Precigen’s recurring technology references include the AdenoVerse immunotherapy platform, UltraCAR-T programs, and related manufacturing capabilities used to support its precision-medicine portfolio.
Precigen ActoBio, a clinical-stage biotechnology firm, announced the successful completion of the primary endpoint in its Phase 1b study of AG019, focusing on safety and tolerability for early-onset type 1 diabetes. The study showed that AG019, an oral capsule, was well tolerated with no serious adverse events reported. Notably, 67% of patients exhibited a slower decline in C-peptide levels, indicating potential disease modification. The ongoing Phase 2a study will further evaluate AG019 in combination with teplizumab. This promising data supports continued development of AG019 in targeting type 1 diabetes.
Precigen Triple-Gene, a subsidiary of Precigen (Nasdaq: PGEN), has announced promising six-month follow-up data from its Phase I trial of INXN-4001, a multigenic gene therapy for heart failure. This therapy targets myocardial remodeling via retrograde coronary sinus infusion. The study met primary safety and feasibility endpoints, with no adverse events linked to the therapy. Additionally, 50% of evaluated patients showed improved quality of life and walking distance at follow-up. Final study results are expected in 12 months.
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company, will release its second quarter and first half 2020 financial results on August 10, 2020, after market close. A conference call will follow at 4:30 PM ET to discuss these results along with a general business update. Precigen focuses on innovative gene and cell therapies targeting critical diseases, maintaining a preclinical and clinical pipeline. The company emphasizes its commitment to advancing precise, affordable biotherapeutics for various medical challenges.
Precigen announced preclinical data for its investigational PRGN-3005 UltraCAR-T aimed at treating advanced ovarian cancer, presented during the AACR Virtual Annual Meeting II. The data indicates that UltraCAR-T, generated through a rapid, non-viral process, shows superior efficacy and persistence compared to traditional CAR-T therapies. In preclinical trials, all treated mice became tumor-free after receiving PRGN-3005, and the treatment demonstrated durability upon tumor rechallenge. The FDA has approved the IND for a Phase I clinical trial that is currently underway.